PubRank

Lorenzo Galluzzi

Author PubWeight™ 184.61‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Mitochondrial membrane permeabilization in cell death. Physiol Rev 2007 12.72
2 Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol 2010 9.06
3 Immunogenic cell death in cancer therapy. Annu Rev Immunol 2012 6.59
4 Regulation of autophagy by cytoplasmic p53. Nat Cell Biol 2008 5.97
5 Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011 5.62
6 An immunosurveillance mechanism controls cancer cell ploidy. Science 2012 4.35
7 Targeting mitochondria for cancer therapy. Nat Rev Drug Discov 2010 4.07
8 Mitochondria and the autophagy-inflammation-cell death axis in organismal aging. Science 2011 3.74
9 Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 2013 3.73
10 Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol 2011 3.40
11 Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 2013 3.26
12 Autophagy regulation by p53. Curr Opin Cell Biol 2010 2.56
13 Cell death assays for drug discovery. Nat Rev Drug Discov 2011 2.51
14 The IKK complex contributes to the induction of autophagy. EMBO J 2009 2.41
15 Spermidine and resveratrol induce autophagy by distinct pathways converging on the acetylproteome. J Cell Biol 2011 2.23
16 Nonapoptotic role for Apaf-1 in the DNA damage checkpoint. Mol Cell 2007 2.20
17 Cytoplasmic STAT3 represses autophagy by inhibiting PKR activity. Mol Cell 2012 2.14
18 Involvement of p38alpha in the mitotic progression of p53(-/-) tetraploid cells. Cell Cycle 2010 2.08
19 Decoding cell death signals in liver inflammation. J Hepatol 2013 2.05
20 Mutant p53 protein localized in the cytoplasm inhibits autophagy. Cell Cycle 2008 2.03
21 Methods for assessing autophagy and autophagic cell death. Methods Mol Biol 2008 1.96
22 Role of the c subunit of the FO ATP synthase in mitochondrial permeability transition. Cell Cycle 2013 1.94
23 Anti- and pro-tumor functions of autophagy. Biochim Biophys Acta 2009 1.92
24 Autophagy is required for the activation of NFκB. Cell Cycle 2012 1.89
25 Liver mitochondrial membrane crosslinking and destruction in a rat model of Wilson disease. J Clin Invest 2011 1.86
26 Inflammasomes in carcinogenesis and anticancer immune responses. Nat Immunol 2012 1.85
27 Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology 2012 1.78
28 Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev 2011 1.76
29 Autophagy and cellular immune responses. Immunity 2013 1.71
30 Multipolar mitosis of tetraploid cells: inhibition by p53 and dependency on Mos. EMBO J 2010 1.64
31 Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. Sci Transl Med 2012 1.63
32 Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia. Cell Cycle 2011 1.59
33 Autophagy mediates pharmacological lifespan extension by spermidine and resveratrol. Aging (Albany NY) 2009 1.48
34 Regulation of autophagy by stress-responsive transcription factors. Semin Cancer Biol 2013 1.44
35 Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study. Blood 2007 1.43
36 A yeast BH3-only protein mediates the mitochondrial pathway of apoptosis. EMBO J 2011 1.42
37 Trial watch: Monoclonal antibodies in cancer therapy. Oncoimmunology 2013 1.41
38 Senescence, apoptosis or autophagy? When a damaged cell must decide its path--a mini-review. Gerontology 2008 1.40
39 Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology 2013 1.36
40 Trial Watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology 2013 1.35
41 Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 2012 1.33
42 TP53 and MTOR crosstalk to regulate cellular senescence. Aging (Albany NY) 2010 1.32
43 Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 2013 1.31
44 Trial Watch: Anticancer radioimmunotherapy. Oncoimmunology 2013 1.31
45 Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012 1.30
46 Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone. Cancer Res 2008 1.29
47 Prerequisites for the antitumor vaccine-like effect of chemotherapy and radiotherapy. Cancer J 2011 1.28
48 Pro-autophagic polyphenols reduce the acetylation of cytoplasmic proteins. Cell Cycle 2012 1.27
49 A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib. Cancer Res 2007 1.26
50 Mitochondrial apoptosis without VDAC. Nat Cell Biol 2007 1.24
51 Inhibition of Chk1 kills tetraploid tumor cells through a p53-dependent pathway. PLoS One 2007 1.23
52 Pyroptosis - a cell death modality of its kind? Eur J Immunol 2010 1.23
53 CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy. Cancer Res 2013 1.22
54 Trial watch: Cardiac glycosides and cancer therapy. Oncoimmunology 2013 1.21
55 Trial Watch: Immunostimulatory cytokines. Oncoimmunology 2012 1.19
56 Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology 2012 1.17
57 Inhibition of autophagy by TAB2 and TAB3. EMBO J 2011 1.15
58 Mitochondrial control of cell death induced by hyperosmotic stress. Apoptosis 2007 1.15
59 Surface-exposed calreticulin in the interaction between dying cells and phagocytes. Ann N Y Acad Sci 2010 1.12
60 Mitochondrial control of the NLRP3 inflammasome. Nat Immunol 2011 1.12
61 Viral subversion of immunogenic cell death. Cell Cycle 2009 1.12
62 Immunohistochemical detection of cytoplasmic LC3 puncta in human cancer specimens. Autophagy 2012 1.12
63 Trial watch: DNA vaccines for cancer therapy. Oncoimmunology 2013 1.11
64 p53 inhibits autophagy by interacting with the human ortholog of yeast Atg17, RB1CC1/FIP200. Cell Cycle 2011 1.11
65 Hormesis, cell death and aging. Aging (Albany NY) 2011 1.11
66 Cisplatin resistance associated with PARP hyperactivation. Cancer Res 2013 1.11
67 Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology 2013 1.09
68 Oncosuppressive functions of autophagy. Antioxid Redox Signal 2010 1.06
69 Premortem autophagy determines the immunogenicity of chemotherapy-induced cancer cell death. Autophagy 2012 1.06
70 The life span-prolonging effect of sirtuin-1 is mediated by autophagy. Autophagy 2010 1.05
71 p53 represses the polyploidization of primary mammary epithelial cells by activating apoptosis. Cell Cycle 2009 1.02
72 Functions of BCL-X L at the Interface between Cell Death and Metabolism. Int J Cell Biol 2013 1.02
73 ATP-dependent recruitment, survival and differentiation of dendritic cell precursors in the tumor bed after anticancer chemotherapy. Oncoimmunology 2013 1.01
74 Loss-of-function alleles of P2RX7 and TLR4 fail to affect the response to chemotherapy in non-small cell lung cancer. Oncoimmunology 2012 1.00
75 Erlotinib antagonizes constitutive activation of SRC family kinases and mTOR in acute myeloid leukemia. Cell Cycle 2011 1.00
76 Trial Watch: Immunostimulatory cytokines. Oncoimmunology 2013 0.96
77 Trial Watch: Adoptive cell transfer for anticancer immunotherapy. Oncoimmunology 2013 0.95
78 Mechanisms of p53-mediated mitochondrial membrane permeabilization. Cell Res 2008 0.94
79 Immunosurveillance against tetraploidization-induced colon tumorigenesis. Cell Cycle 2013 0.94
80 Selective killing of p53-deficient cancer cells by SP600125. EMBO Mol Med 2012 0.94
81 Immunosurveillance as a regulator of tissue homeostasis. Trends Immunol 2013 0.93
82 IKK connects autophagy to major stress pathways. Autophagy 2010 0.92
83 Current trends of anticancer immunochemotherapy. Oncoimmunology 2013 0.91
84 Crosstalk between ER stress and immunogenic cell death. Cytokine Growth Factor Rev 2013 0.91
85 Victories and deceptions in tumor immunology: Stimuvax(®) Oncoimmunology 2013 0.91
86 Anticancer activity of cardiac glycosides: At the frontier between cell-autonomous and immunological effects. Oncoimmunology 2012 0.91
87 Antiapoptotic activity of argon and xenon. Cell Cycle 2013 0.91
88 A chemical inhibitor of Apaf-1 exerts mitochondrioprotective functions and interferes with the intra-S-phase DNA damage checkpoint. Apoptosis 2009 0.91
89 Apaf-1 Deficiency Causes Chromosomal Instability. Cell Cycle 2007 0.90
90 Direct molecular interactions between Beclin 1 and the canonical NFκB activation pathway. Autophagy 2012 0.90
91 Erlotinib antagonizes ABC transporters in acute myeloid leukemia. Cell Cycle 2012 0.89
92 A new role for cytoplasmic p53: binding and destroying double-stranded RNA. Cell Cycle 2010 0.88
93 Chk1 inhibition activates p53 through p38 MAPK in tetraploid cancer cells. Cell Cycle 2008 0.87
94 Erlotinib and gefitinib for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a preclinical comparison. Biochem Pharmacol 2008 0.87
95 Preferential killing of p53-deficient cancer cells by reversine. Cell Cycle 2012 0.86
96 Direct interaction between STAT3 and EIF2AK2 controls fatty acid-induced autophagy. Autophagy 2012 0.85
97 Tumor necrosis factor is dispensable for the success of immunogenic anticancer chemotherapy. Oncoimmunology 2013 0.84
98 Longevity-relevant regulation of autophagy at the level of the acetylproteome. Autophagy 2011 0.83
99 An anticancer therapy-elicited immunosurveillance system that eliminates tetraploid cells. Oncoimmunology 2013 0.83
100 EGFR inhibitors exacerbate differentiation and cell cycle arrest induced by retinoic acid and vitamin D3 in acute myeloid leukemia cells. Cell Cycle 2013 0.83
101 Novel inducers of BECN1-independent autophagy: cis-unsaturated fatty acids. Autophagy 2015 0.82
102 Novel multifunctional antibody approved for the treatment of breast cancer. Oncoimmunology 2013 0.82
103 Disruption of the PP1/GADD34 complex induces calreticulin exposure. Cell Cycle 2009 0.82
104 Nutlin kills cancer cells via mitochondrial p53. Cell Cycle 2009 0.82
105 Metabolomic analyses reveal that anti-aging metabolites are depleted by palmitate but increased by oleate in vivo. Cell Cycle 2015 0.81
106 NF-kappaB blockade upregulates Bax, TSP-1, and TSP-2 expression in rat granulation tissue. J Mol Med (Berl) 2009 0.80
107 Fluorescent biosensors for the detection of HMGB1 release. Methods Mol Biol 2013 0.80
108 Novel insights into the mitochondrial permeability transition. Cell Cycle 2014 0.80
109 Transgenerational cell fate profiling: a method for the graphical presentation of complex cell cycle alterations. Cell Cycle 2012 0.79
110 Immunosurveillance against cancer-associated hyperploidy. Oncotarget 2012 0.79
111 Cytofluorometric assessment of cell cycle progression. Methods Mol Biol 2013 0.79
112 Cytofluorometric purification of diploid and tetraploid cancer cells. Methods Mol Biol 2011 0.79
113 3' self-inactivating long terminal repeat inserts for the modulation of transgene expression from lentiviral vectors. Hum Gene Ther Methods 2012 0.78
114 Immunological control of cell cycle aberrations for the avoidance of oncogenesis: the case of tetraploidy. Ann N Y Acad Sci 2013 0.76
115 Preface: oncometabolism: a new field of research with profound therapeutic implications. Methods Enzymol 2014 0.75
116 Quantification of cell cycle-arresting proteins. Methods Mol Biol 2013 0.75
117 Preface: oncometabolism: a new field of research with profound therapeutic implications. Methods Enzymol 2014 0.75